Fluphenazine decanoate Chemical Properties

Melting point:

30-32°

Boiling point:

658.1±55.0 °C(Predicted)

Density 

1.149±0.06 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

Practically insoluble in water, very soluble in ethanol and in methylene chloride, freely soluble in methanol.

form 

Oil

pka

7.32±0.10(Predicted)

color 

Light yellow to yellow

Major Application

pharmaceutical (small molecule)

InChIKey

VIQCGTZFEYDQMR-UHFFFAOYSA-N

SMILES

FC(F)(F)c1cc2c(cc1)Sc3c(cccc3)N2CCCN4CCN(CC4)CCOC(=O)CCCCCCCCC

CAS DataBase Reference

5002-47-1

Safety Information

RIDADR 

3249

WGK Germany 

WGK 3

RTECS 

HE0525000

HazardClass 

6.1(a)

PackingGroup 

II

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2
very toxic hazardous materials

Hazard Classifications

Acute Tox. 2 Oral
Repr. 2

Fluphenazine decanoate Usage And Synthesis

Chemical Properties

Yellow Oil

Uses

Fluphenazine Decanoate is used in psychotropic drug treatments like those relating to schizophrenia. Antipsychotic.

Definition

ChEBI: Fluphenazine decanoate is the prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia. It has a role as a phenothiazine antipsychotic drug, a prodrug and a dopaminergic antagonist. It is a member of phenothiazines, a decanoate ester, an organofluorine compound and a N-alkylpiperazine. It is functionally related to a fluphenazine.

Clinical Use

Antipsychotic
Schizophrenia and other psychoses

Drug interactions

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids.
Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; increased risk of ventricular arrhythmias with amiodarone and dronedarone - avoid; increased risk of ventricular arrhythmias with disopyramide.
Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin - avoid
Antidepressants: increased risk of ventricular arrhythmias with tricyclics, citalopram, escitalopram; possible increased risk of convulsions with vortioxetine
Antiepileptics: antagonises anticonvulsant effect.
Antimalarials: increased risk of ventricular arrhythmias with artenimol with piperaquine and artemether/lumefantrine - avoid.
Antipsychotics: increased risk of ventricular arrhythmias with droperidol, pimozide and risperidone - avoid; avoid use of depot formulations with clozapine (cannot be withdrawn quickly if neutropenia occurs).
Antivirals: increased risk of ventricular arrhythmias with saquinavir - avoid; concentration possibly increased with ritonavir.
Anxiolytics and hypnotics: increased sedative effects
Atomoxetine: increased risk of ventricular arrhythmias.
Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol
Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide
Diuretics: enhanced hypotensive effect.
Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
Pentamidine: increased risk of ventricular arrhythmias - avoid.
Avoid with drugs that prolong the QT interval.

Metabolism

The cytochrome P450 isoenzyme CYP2D6 is involved in fluphenazine metabolism.

Fluphenazine decanoate (5002-47-1)Related Product Information

• Levodropropizine
• 2-Ethylhexyl ferulate
• Piperacillin
• [(3S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] decanoate
• Prochlorperazine
• FLUPHENAZINE HYDROCHLORIDE
• N-Aminoethylpiperazine
• Phenothiazine
• FLUPHENAZINE
• Piperazine
• 2-(Trifluoromethyl)phenothiazine
• Trifluoperazine
• 10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine
• triflupromazine
• 1-(2-ETHOXYETHYL)PIPERAZINE
• 1-[2-(1-PROPYL)-OXYETHYL]-PIPERAZINE
• fluphenazine O-enantate
• Fluphenazine decanoate